The oncoprotein HBXIP facilitates metastasis of hepatocellular carcinoma cells by activation of MMP15 expression

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.2126225651787
   PubMed Web of Science ®Google Scholar
• Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 2012;62(6):394–399. doi:10.3322/caac.2116123070690
   PubMed Web of Science ®Google Scholar
• Goh GB, Chang PE, Tan CK. Changing epidemiology of hepatocellular carcinoma in Asia. Best Pract Res Clin Gastroenterol. 2015;29(6):919–928. doi:10.1016/j.bpg.2015.09.00726651253
   PubMed Web of Science ®Google Scholar
• Melegari M, Scaglioni PP, Wands JR. Cloning and characterization of a novel hepatitis B virus x binding protein that inhibits viral replication. J Virol. 1998;72(3):1737–1743.9499022
   PubMed Web of Science ®Google Scholar
• Wang Y, Li N, Che S, et al. HBXIP suppression reduces cell proliferation and migration and its overexpression predicts poor prognosis in non-small-cell lung cancer. Tumour Biol. 2017;39(7):1010428317709675. doi:10.1177/101042831770967528718367
   PubMedGoogle Scholar
• Wang Y, Sun J, Li N, et al. HBXIP overexpression is correlated with the clinical features and survival outcome of ovarian cancer. J Ovarian Res. 2017;10(1):26. doi:10.1186/s13048-017-0322-728388957
   PubMedGoogle Scholar
• Cheng D, Liang B, Li Y. HBXIP expression predicts patient prognosis in breast cancer. Med Oncol. 2014;31(10):210. doi:10.1007/s12032-014-0374-025178941
   PubMed Web of Science ®Google Scholar
• Zhou X, Wang X, Duan J, et al. HBXIP protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas. Pathol Res Pract. 2019;215(2):343–346. doi:10.1016/j.prp.2018.12.01630583814
   PubMed Web of Science ®Google Scholar
• Xia H, Ma L, Li J, Bai H, Wang D. Elevated HBXIP expression is associated with aggressive phenotype and poor prognosis in esophageal squamous cell carcinoma. Am J Cancer Res. 2017;7(11):2190–2198.29218243
   PubMed Web of Science ®Google Scholar
• Jiang Y, Wang D, Ren H, Shi Y, Gao Y. Oncogenic HBXIP enhances ZEB1 through Sp1 to accelerate breast cancer growth. Thorc Cancer. 2018;9(12):1664–1670. doi:10.1111/1759-7714.12878
   PubMed Web of Science ®Google Scholar
• Yue L, Li L, Liu F, et al. The oncoprotein HBXIP activates transcriptional coregulatory protein LMO4 via Sp1 to promote proliferation of breast cancer cells. Carcinogenesis. 2013;34(4):927–935. doi:10.1093/carcin/bgs39923291272
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhao Y, Li L, et al. The oncoprotein HBXIP upregulates PDGFB via activating transcription factor Sp1 to promote the proliferation of breast cancer cells. Biochem Biophys Res Commun. 2013;434(2):305–310. doi:10.1016/j.bbrc.2013.02.12323537647
   PubMed Web of Science ®Google Scholar
• Shi H, Li Y, Feng G, et al. The oncoprotein HBXIP up-regulates FGF4 through activating transcriptional factor Sp1 to promote the migration of breast cancer cells. Biochem Biophys Res Commun. 2016;471(1):89–94. doi:10.1016/j.bbrc.2016.01.17426828265
   PubMed Web of Science ®Google Scholar
• Wang Y, Cai X, Zhang S, et al. HBXIP up-regulates ACSL1 through activating transcriptional factor Sp1 in breast cancer. Biochem Biophys Res Commun. 2017;484(3):565–571. doi:10.1016/j.bbrc.2017.01.12628132807
   PubMed Web of Science ®Google Scholar
• Xu F, You X, Liu F, et al. The oncoprotein HBXIP up-regulates Skp2 via activating transcription factor E2F1 to promote proliferation of breast cancer cells. Cancer Lett. 2013;333(1):124–132. doi:10.1016/j.canlet.2013.01.02923352642
   PubMed Web of Science ®Google Scholar
• Liu BW, Wang TJ, Li LL, et al. Oncoprotein HBXIP induces PKM2 via transcription factor E2F1 to promote cell proliferation in ER-positive breast cancer. Acta Pharmacol Sin.  2019 Apr;40(4):530–538.
   Web of Science ®Google Scholar
• Liu F, You X, Wang Y, et al. The oncoprotein HBXIP enhances angiogenesis and growth of breast cancer through modulating FGF8 and VEGF. Carcinogenesis. 2014;35(5):1144–1153. doi:10.1093/carcin/bgu02124464787
   PubMed Web of Science ®Google Scholar
• Li Y, Wang Z, Shi H, et al. HBXIP and LSD1 scaffolded by lncRNA hotair mediate transcriptional activation by c-Myc. Cancer Res. 2016;76(2):293–304. doi:10.1158/0008-5472.CAN-14-360726719542
   PubMed Web of Science ®Google Scholar
• Wang Y, Cui M, Cai X, et al. The oncoprotein HBXIP up-regulates SCG3 through modulating E2F1 and miR-509-3p in hepatoma cells. Cancer Lett. 2014;352(2):169–178. doi:10.1016/j.canlet.2014.05.00724882622
   PubMed Web of Science ®Google Scholar
• Wang Y, Fang R, Cui M, et al. The oncoprotein HBXIP up-regulates YAP through activation of transcription factor c-Myb to promote growth of liver cancer. Cancer Lett. 2017;385:234–242. doi:10.1016/j.canlet.2016.10.01827765671
   PubMed Web of Science ®Google Scholar
• Shi H, Fang R, Li Y, et al. The oncoprotein HBXIP suppresses gluconeogenesis through modulating PCK1 to enhance the growth of hepatoma cells. Cancer Lett. 2016;382(2):147–156. doi:10.1016/j.canlet.2016.08.02527609066
   PubMed Web of Science ®Google Scholar
• Ruan L, Huang L, Zhao L, et al. The interaction of lncRNA-HEIH and lncRNA-HULC with HBXIP in Hepatitis B Patients. Gastroenterol Res Pract. 2018;2018:9187316. doi:10.1155/2018/918731630622563
   PubMed Web of Science ®Google Scholar
• Haas CS, Gleason B, Lin S, Tramonti G, Kanwar YS. Matrix metalloproteinases in renal development. Connect Tissue Res. 2004;45(2):73–85. doi:10.1080/0300820049044264415763922
   PubMed Web of Science ®Google Scholar
• Tomlinson ML, Garcia-Morales C, Abu-Elmagd M, Wheeler GN. Three matrix metalloproteinases are required in vivo for macrophage migration during embryonic development. Mech Dev. 2008;125(11–12):1059–1070. doi:10.1016/j.mod.2008.07.00518684398
   PubMed Web of Science ®Google Scholar
• Maciejczyk M, Pietrzykowska A, Zalewska A, Knas M, Daniszewska I. The significance of matrix metalloproteinases in oral diseases. Adv Clin Exp Med. 2016;25(2):383–390. doi:10.17219/acem/3042827627574
   PubMed Web of Science ®Google Scholar
• Zhang M, Dai C, Zhu H, et al. Cyclophilin A promotes human hepatocellular carcinoma cell metastasis via regulation of MMP3 and MMP9. Mol Cell Biochem. 2011;357(1–2):387–395. doi:10.1007/s11010-011-0909-z21667159
   PubMed Web of Science ®Google Scholar
• Huang D, Du X, Yuan R, et al. Rock2 promotes the invasion and metastasis of hepatocellular carcinoma by modifying MMP2 ubiquitination and degradation. Biochem Biophys Res Commun. 2014;453(1):49–56. doi:10.1016/j.bbrc.2014.09.06125251472
   PubMed Web of Science ®Google Scholar
• Chen J, Xu W, Chen Y, et al. Matrix metalloproteinase 9 facilitates hepatitis B virus replication through binding with type i interferon (IFN) receptor 1 to repress IFN/JAK/STAT signaling. J Virol. 2017;91(8). doi:10.1128/JVI.00955-17
   Web of Science ®Google Scholar
• Hemmann S, Graf J, Roderfeld M, Roeb E. Expression of MMPs and TIMPs in liver fibrosis – a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol. 2007;46(5):955–975. doi:10.1016/j.jhep.2007.02.00317383048
   PubMed Web of Science ®Google Scholar
• Zhao Y, Li H, Zhang Y, et al. Oncoprotein HBXIP modulates abnormal lipid metabolism and growth of breast cancer cells by activating the LXRs/SREBP-1c/FAS signaling cascade. Cancer Res. 2016;76(16):4696–4707. doi:10.1158/0008-5472.CAN-15-173426980761
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–1127. doi:10.1056/NEJMra100168321992124
   PubMed Web of Science ®Google Scholar
• Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127(4):679–695. doi:10.1016/j.cell.2006.11.00117110329
   PubMed Web of Science ®Google Scholar
• Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52–67. doi:10.1016/j.cell.2010.03.01520371345
   PubMed Web of Science ®Google Scholar
• Sipos F, Firneisz G, Muzes G. Therapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseases. World J Gastroenterol. 2016;22(35):7938–7950. doi:10.3748/wjg.v22.i35.793827672289
   PubMed Web of Science ®Google Scholar